Quality of life should be the primary outcome for disease modifying therapy trials in MS—No

Detalles Bibliográficos
Autores principales: Strijbis, EMM, Koch, MW, de Jong, BA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Controversies in Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413779/
https://www.ncbi.nlm.nih.gov/pubmed/37489564
http://dx.doi.org/10.1177/13524585231182708
_version_ 1785087203744940032
author Strijbis, EMM
Koch, MW
de Jong, BA
author_facet Strijbis, EMM
Koch, MW
de Jong, BA
author_sort Strijbis, EMM
collection PubMed
description
format Online
Article
Text
id pubmed-10413779
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104137792023-08-11 Quality of life should be the primary outcome for disease modifying therapy trials in MS—No Strijbis, EMM Koch, MW de Jong, BA Mult Scler Controversies in Multiple Sclerosis SAGE Publications 2023-07-25 2023-08 /pmc/articles/PMC10413779/ /pubmed/37489564 http://dx.doi.org/10.1177/13524585231182708 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Controversies in Multiple Sclerosis
Strijbis, EMM
Koch, MW
de Jong, BA
Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title_full Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title_fullStr Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title_full_unstemmed Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title_short Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
title_sort quality of life should be the primary outcome for disease modifying therapy trials in ms—no
topic Controversies in Multiple Sclerosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413779/
https://www.ncbi.nlm.nih.gov/pubmed/37489564
http://dx.doi.org/10.1177/13524585231182708
work_keys_str_mv AT strijbisemm qualityoflifeshouldbetheprimaryoutcomefordiseasemodifyingtherapytrialsinmsno
AT kochmw qualityoflifeshouldbetheprimaryoutcomefordiseasemodifyingtherapytrialsinmsno
AT dejongba qualityoflifeshouldbetheprimaryoutcomefordiseasemodifyingtherapytrialsinmsno

Ejemplares similares